MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
Open Access
- 17 February 2026
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 40 (4) , 832-836
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaHemaSphere, 2025
- Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myelomaBlood Cancer Journal, 2025
- Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter studyHemaSphere, 2025
- EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJournal for ImmunoTherapy of Cancer, 2024
- Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort studyeClinicalMedicine, 2024
- Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myelomaLeukemia, 2024
- Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insightsEuropean Journal of Preventive Cardiology, 2023
- Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophyClinical Research in Cardiology, 2022
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myelomaAmerican Journal of Hematology, 2016